Abstract Body

In the early days of the COVID-19 pandemic, the HIV community became preoccupied that COVID-19 could be more severe in people with HIV (PWH) because of immunodeficiency, higher prevalence of comorbidities and immunosenescence, which had been associated with poorer COVID-19 outcomes. Nonetheless, HIV was not initially identified as disproportionally prevalent in hospitalized patients with COVID-19, an observation that still holds. It was also argued that because of immune dysfunction, PWH could be less likely to develop the harsh immunologic response that complicates COVID-19 and that some antiretroviral drugs could impair SARS-CoV-2 replication. Numerous studies have been published since, some with apparently contradictory conclusions. Different epidemiological designs and information sources have been used from case reports to population-based cohorts. Some have compared PWH to people without HIV; others have made comparisons across PWH with different characteristics. Some have reported higher COVID-19 mortality in PWH compared with people without whereas others have not, but there are important differences in the comparison populations and confounders adjusted for. Associations between CD4 cell counts and COVID-19 outcomes are not consistent. The role of protease inhibitors on SARS-CoV-2 RNA-dependent RNA-polymerase has been ruled out, but evidence of effects of tenofovir disoproxil fumarate is accumulating from observational studies. Some of the well established risk factors for SARS-CoV-2 acquisition—high mobility and social interaction, belonging to racial and ethnic minorities and socially disadvantaged groups—are more common in PWH than in people without. Some of the risk factors for COVID-19 severity—hypertension, diabetes mellitus, chronic obstructive pulmonary disease, renal disease and cancer—are also more common in PWH than in populations without HIV of similar age and sex. This presentation will summarize the state of the art and will highlight the importance of the choice of the groups against which COVID-19 outcomes in PWH are compared. Finally, it will also address that in order to establish the effect of HIV on SARS-CoV-2 susceptibility and COVID-19 severity, it is necessary to control for confounding variables that may be partly or fully responsible for the reported associations. It is also important to understand the role of comorbidities that are more common in PWH and may be the result of HIV infection.